**Bevacizumab**

**Core Concept**
Bevacizumumab is a recombinant humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), a key protein involved in angiogenesis. By inhibiting VEGF-A, bevacizumab prevents the formation of new blood vessels, thereby suppressing tumor growth.

**Why the Correct Answer is Right**
Bevacizumab binds to VEGF-A with high affinity, preventing its interaction with VEGF receptors on endothelial cells. This inhibition of VEGF-A signaling pathway disrupts the angiogenic process, which is crucial for tumor growth and metastasis. As a result, bevacizumab exerts its anti-tumor effects by reducing tumor blood supply and hindering tumor progression.

**Why Each Wrong Option is Incorrect**
**Option A:** This option does not provide any information about bevacizumab's mechanism of action or its intended use.
**Option B:** Bevacizumab is not a chemotherapy agent; it is a targeted therapy that specifically inhibits angiogenesis.
**Option C:** While bevacizumab can be used in combination with chemotherapy, it is not a chemotherapeutic agent itself.

**Clinical Pearl / High-Yield Fact**
Bevacizumab is one of the first monoclonal antibodies to be approved for the treatment of cancer, and its use has expanded to various types of tumors, including colorectal, breast, lung, and renal cell carcinomas.

**Correct Answer: D. Anti-angiogenic monoclonal antibody**